Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a new tool designed to accelerate AI-powered high-throughput screening for antibody drug discovery. The kit leverages cell-free protein synthesis technology to produce target proteins and antibodies in vitro, eliminating the constraints of traditional cell-based expression systems. By integrating with AI screening platforms, it aims to speed up the identification and optimization of antibody candidates while reducing costs and development timelines.
The XPressMAX™ kit is based on an E. coli lysate and is fully supplemented with essential transcription and translation components, enabling direct protein synthesis from plasmid or PCR templates. It is specifically designed for antibody drug discovery, supporting rapid expression and validation of VHH, scFv, Fab, and miniproteins. Sino Biological has established a high-throughput cell-free expression platform using XPressMAX™ that can validate over 2,000 scFv/VHH molecules in 3 to 4 weeks, matching the rapid iteration of AI systems.
Key features of the kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding without additional enhancers, ensuring native folding and bioactivity. According to Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., 'Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.' Dr. Jie Zhang, General Manager of Sino Biological, added, 'AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.'
Researchers can visit the product page at https://www.sinobiological.com/other-products/cell-free-protein-synthesis-system-cfkit02 for more details or explore the company's cell-free solutions at https://www.sinobiological.com/category/solutions/cell-free. Free samples are available through a request form at https://forms.gle/T88f1RBLnF5Gj43P7.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored, localized solutions to researchers in over 90 countries. The launch of XPressMAX™ underscores the company's commitment to advancing drug discovery through innovative technologies that address the growing demands of AI-driven research.